Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.4%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price dropped 4.4% during mid-day trading on Thursday . The company traded as low as $9.54 and last traded at $9.57. Approximately 2,189,670 shares were traded during trading, a decline of 65% from the average daily volume of 6,331,738 shares. The stock had previously closed at $10.01.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a report on Friday, May 10th. TD Cowen started coverage on shares of Recursion Pharmaceuticals in a report on Friday, January 26th. They set a "market perform" rating for the company. Finally, KeyCorp upped their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an "overweight" rating in a report on Monday, March 4th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $12.75.

Recursion Pharmaceuticals Stock Down 5.0 %

The business's 50 day simple moving average is $9.24 and its 200 day simple moving average is $9.38. The company has a market capitalization of $2.23 billion, a PE ratio of -6.26 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The business had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The firm's quarterly revenue was up 14.0% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.65 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the transaction, the chief executive officer now owns 863,524 shares of the company's stock, valued at approximately $6,675,040.52. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CFO Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $11.03, for a total transaction of $275,750.00. Following the completion of the sale, the chief financial officer now owns 1,204,179 shares of the company's stock, valued at $13,282,094.37. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Christopher Gibson sold 50,000 shares of the business's stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the transaction, the chief executive officer now owns 863,524 shares in the company, valued at approximately $6,675,040.52. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 327,946 shares of company stock valued at $3,238,953. Company insiders own 15.75% of the company's stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Oxford Wealth Group LLC acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at approximately $106,000. Carroll Investors Inc bought a new stake in Recursion Pharmaceuticals in the first quarter worth $138,000. Bellevue Group AG raised its holdings in Recursion Pharmaceuticals by 143.6% during the first quarter. Bellevue Group AG now owns 425,249 shares of the company's stock valued at $4,240,000 after buying an additional 250,692 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Recursion Pharmaceuticals by 9.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 62,065 shares of the company's stock worth $619,000 after buying an additional 5,501 shares during the last quarter. Finally, Axxcess Wealth Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 62.6% during the 1st quarter. Axxcess Wealth Management LLC now owns 37,385 shares of the company's stock worth $373,000 after acquiring an additional 14,388 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.